TROP2

Ongoing clinical trials and approved products targeting TROP2, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials
4ongoing imaging trials
0approved products

Target note

Full name
TROP2
Nature
Transmembrane glycoprotein, target of sacituzumab govitecan.
Normal expression
Epithelia.
Value
Assessing expression before an anti-TROP2 antibody-drug conjugate.
Approaches
Antibodies and fragments labeled with ⁸⁹Zr or ⁶⁸Ga.
Indications explored
Triple-negative breast, urothelial and lung cancers.
Points of caution
Early stage.

Ongoing imaging trials · 4Open in the radar →

TrialPhaseStatusSponsorCountries
TROP2 tracersNCT06851663 · Prostate – otherPhase 3RecruitingRenJi Hospital1
TROP2 tracersNCT07685197 · Small-cell lung cancerPhase 2Not yet recruitingZhou Chengzhi0
TROP2 tracersNCT07177482 · OtherNo phaseRecruitingDeling Li1
TROP2 tracersNCT06104085 · BreastNo phaseRecruitingPeking Union Medical College Hospital1

Cite this page

TROP2. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/trop2/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.